Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00573989 · OUTCOME

Progression-free Survival (PFS) at 1 Year (Phase II)

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
1 year

What was measured

Determine Progression Free Survival at 1 year defined as the percentage of patients who are alive at 1 year after beginning of their concurrent re-irradiation and chemotherapy without loco-regional progression of their disease as measured by CT scan or MRI.

Analysis population: Data corresponds to Phase II patients.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Erlotinib12

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
Determine Progression Free Survival at 1 year defined as the percentage of patients who are alive at 1 year after beginning of their concurrent re-irradiation and chemotherapy without loco-regional progression of their disease as measured by CT scan or MRI.
groups
  1. description
    Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
    id
    OG000
    title
    Erlotinib
param Type
COUNT_OF_PARTICIPANTS
population Description
Data corresponds to Phase II patients.
reporting Status
POSTED
time Frame
1 year
title
Progression-free Survival (PFS) at 1 Year (Phase II)
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice